sociated with hemorrhagic colitis (lOa, 29b, 34) and hemolytic-uremic syndrome (HUS) (lla, 38a, 44) . These strains produce Shiga-like toxins (SLT), also called Vero toxins (VT) (14) , that are cytotoxic for both Vero cells and HeLa cells. There are two antigenically distinct groups of SLT: SLT-I and SLT-II (for reviews, see references 11, 27, and 39) . Members of the SLT-I group appear to be antigenically homogeneous, but evidence of a diverse but related family of SLT-II toxins is growing. The nucleotide sequences of two toxin operons closely related to SLT-II and found in an E. coli 091:H21 strain isolated from a patient with HUS were recently presented (9) . This characterization of the vtx2ha and vtx2hb genes from strain B2F1 was the first demonstration of multiple copies of toxin genes related to SLT-II present within a single strain (9) .
It has been proposed that the E. coli 0157:H-strain E32511 produces yet another distinct toxin in the SLT-II (VT2) family (5a) . Two variants of SLT-II have been well characterized (4, 46) . The variants, designated SLT-IIv and SLT-IIva, unlike SLT-II, are cytotoxic for Vero but not HeLa cells. The difference in cytotoxicity for Vero and HeLa cells between SLT-II and SLT-IIv may be due to different receptor specificities (35) . SLT-IIv is the causative agent of edema disease in pigs (15, 22) , while SLT-IIva has been associated with diarrhea in a human infant (4) .
Toxins produced by E. coli 933 and E32511 have been studied for production of SLT-II and VT2, respectively (37a, 41) . The terms SLT and VT are used interchangeably to describe these toxins; however, it is not clear whether SLT-II and VT2 are identical toxins. Both toxins are found on and have been cloned from bacteriophages (25, 38a, 42, 48) . The sequence of the slt-II operon from 933 is known * Corresponding author. (10) . However, reports on the capacities of various anti-SLT (VT) sera to neutralize toxin preparations from 933 and E32511 have been somewhat contradictory. Two groups concluded that SLT-II of 933 and VT2 of strain E32511 are similar or identical by serological criteria (41, 49) , while two other groups indicated that SLT-II from strain 933 and VT2 from strain E32511 are antigenically distinct but related (2, Sa) . In this study, 32 clinical isolates were examined to determine the prevalence of multiple copies of similar toxin genes. In addition, we report the cloning, sequencing, and antigenic characterization of two toxin operons from E. coli 0157:H-strain E32511. The nucleotide sequences of the toxin genes were compared with those of other toxin genes in the SLT-II family.
MATERIALS AND METHODS
Plasmids, phages, and strains. Plasmids, phages, and bacterial strains used in this study are listed and described in Tables 1 and 3 .
Media, enzymes, biochemicals, and radionuclides. Strains were routinely grown in L broth (24) for 18 h at 37°C. When necessary, antibiotics (Sigma Chemical Co., St. Louis, Mo.) were added to the medium to the following final concentrations: ampicillin (Ap), 100 jig/ml; tetracycline (Tc), 12.5 p,g/ml. Media were also supplemented with 5-bromo-4-chloro-3-indolyl-I3-D-galactopyranoside (X-Gal) and isopro- (20) . Small-scale preparation of total DNA from 1.5-ml cultures of clinical isolates was performed as described in Current Protocols in Molecular Biology (1) . Plasmid DNA was isolated by the method of Holmes and Quigley (8) . Host cells were made competent to take up DNA by calcium chloride and heat shock (17) . Procedures for cosmid cloning and subcloning were those of Maniatis et al. (18) . Cosmids were packaged by using the Stratagene Gigapack II Gold Packaging Extract.
DNA hybridization studies. Chromosomal and plasmid DNAs were probed with slt-specific sequences by in situ gel hybridization (12a) with the following modifications. Gels were not prehybridized, and 20 mM sodium pyrophosphate was included in the hybridization solution as a blocking agent. Washing conditions were as follows. One wash was done in 2x SSC (lx SSC is 0.15 M NaCl plus 0.015 M sodium citrate, pH 7.0) at 65°C for 1 h, followed by one wash in 0.1x SSC at 65°C for 1 h. DNA probes specific for slt-I and slt-Il were labeled with [32P]dCTP by nick translation (19) . Clones containing complete or partial toxin genes were identified by colony or plaque hybridization (18) .
Nucleotide sequence analysis. DNA sequencing followed the dideoxy-chain termination method of Sanger et al. (36) as adapted for M13 vectors by Schreier and Cortese (37) . Specifically, the Sequenase kit from U.S. Biochemicals was used for nucleotide sequencing. M13mpl8 and mpl9 vectors were used for cloning and sequencing as described by Messing and coworkers (26) . In addition to the M13 universal sequencing primer, several slt-II-specific synthetic oligonucleotides (Applied Biosystems Incorporated model 380A synthesizer) (10) were used in sequencing.
Cytotoxicity assays. Cytotoxicity assays were done essentially as described by Gentry and Dalrymple (5). Wild-type E. coli and various E. coli clones and subclones were cultured as described above and disrupted by sonic lysis as described previously (28) . The filter-sterilized bacterial lysates were serially diluted in tissue culture medium (Dulbecco modified Eagle medium containing 10% fetal calf serum, 0.8 mM glutamine, 500 U of penicillin G per ml, and 500 mg of streptomycin per ml (40) (Fig. 4) . 1 IgM, immunoglobulin M.
and sera were prepared in this laboratory except BC5 BB12, which was kindly supplied by Nancy Strockbine, Centers for Disease Control, Atlanta, Ga. The F45 antitoxin was prepared against purified Shiga toxin from Shigella dysenteriae type 1 60R; Shiga toxin and SLT-I are essentially the same (40) . AJ65 antitoxin was prepared by immunizing rabbits with crude preparations of sonically disrupted E. coli C600(933W), an SLT-II-producing lysogen. Antibodies BC5 BB12 (ascites fluid) and AJ65 (antiserum) were diluted 10-fold to prepare starting stocks. Starting stocks of hybridoma supernatants (llGlO and 2E1) were not diluted, nor was antiserum F45. Monoclonal antibodies and polyclonal sera to be tested for cytotoxin-neutralizing activity were serially diluted in tissue culture medium. A sample (100 1.d) of diluted toxin (containing approximately 40 times the 50% cytotoxic dose) was added to an equal volume of each antibody dilution and incubated at 37°C for 2 h, followed by incubation at 4°C for 4 h. A sample (100 ,u) of each mixture was then transferred to Vero cells, and the microtiter plates were incubated and tissue culture cells were fixed and stained as described above. Toxin in the absence of antibody killed between 60 and 90% of the tissue culture cells in a well, as determined below. Percent neutralization was determined by the following formula: {[A620(toxin + antibody) -A620(toxin)]/A620 (untreated cells)} x 100.
The experiments reported here were conducted according to the principles set forth in the Guide for the Care and Use of Laboratory Animals (24a).
Nucleotide sequence accession number. The nucleotide sequence of slt-Ilc has been submitted to EMBL and assigned the accession number M59432.
RESULTS
Multiple toxin genes in clinical isolates. To determine the prevalence of multiple copies of toxin genes in clinical isolates, 32 clinical isolates were chosen to be probed with slt-I-and/or slt-II-specific DNA sequences. Earlier studies have shown that 7 of the 32 isolates expressed SLT-I, 1 expressed SLT-IIv, 19 expressed SLT-II, and 5 expressed both SLT-I and SLT-II (21) . Total DNA was isolated, digested with EcoRI, and subjected to electrophoresis through a 0.9% agarose gel. These gels were then probed with toxin-specific probes by in situ gel hybridization. The slt-I probe used was a 913-bp HincII fragment isolated from a partial digest of the plasmid pNAS13 (40) , which encodes slt-I; this HincIl fragment spanned the A and B subunit coding regions. The slt-IT probe used was the 841-bp SmaIPstI fragment of pLP32 (35) , which contains only A subunit gene sequences. Figure 1 shows an example of one gel probed with the slt-IIA sequences. The SLT-I-expressing strain H19 was included to show the specificity of the slt-IIA probe (Fig. 1, lane 2) . Table 3 summarizes results obtained from probing restricted DNA of the 32 clinical isolates with slt-specific fragments. Five strains were identified with two EcoRI fragments that hybridized with the slt-IIA probe ( Fig.  1 ; Table 3 ). In no case were multiple fragments found to hybridize with the slt-I probe.
Cloning of toxin genes from E. coli E32511. Total DNAs from E. coli E32511 and C600(933W) were digested with several restriction endonucleases and subjected to electrophoresis through a 0.9% agarose gel. This gel was then probed with the 841-bp SmaI-PstI fragment of pLP32 to determine the sizes of fragments hybridizing with the A subunit of SLT-II (slt-IIA). Each restriction enzyme used to digest total DNA from the control strain C600(933W) generated a unique fragment that hybridized with the probe (data not shown). However, multiple bands hybridized when E32511 DNA was probed (data not shown), suggesting that more than one copy of a toxin gene may be present. DNA from E32511 digested with EcoRI gave two bands of approximately 4.8 and 5.5 kb which showed hybridization with the slt-IIA probe (Fig. 1, lane 7) .
To characterize the toxin(s) of E32511, a cosmid bank of a Sau3A partial digest was created in the cosmid vector pHC79. Cosmids were initially screened by colony hybridization with the slt-IIA probe and then by in situ gel hybridization using EcoRI-digested cosmid DNA. Several cosmids containing either a 4.8-or a 5.5-kb EcoRI fragment that showed hybridization with the slt-IIA probe were obtained; the two fragments were never found in a single cosmid clone. Representative cosmids containing each fragment were purified for further analysis. Bacterial lysates of E. coli DH5a with cosmids that contained either fragment were cytotoxic for Vero cells, which indicated that an entire toxin operon was present on each clone (data not shown). The two EcoRI fragments of interest were subcloned from the cosmids into the vector pRK415, which yielded the plasmids pCKS109, with the 4.8-kb EcoRI fragment, and pCKS111, with the 5.5-kb EcoRI fragment.
Sequencing of toxin genes. Portions of the toxin genes of E32511 were obtained by isolating the 4.8-or 5.5-kb fragment either from the parent cosmids or from the pRK415 subclones and digesting these with HaeIII, HincIl, or PstI. The products of these restriction digests were then ligated into appropriate M13 vectors; digestion with HaeIII or HincII and subsequent ligation generated a mixture of clones. Clones were selected for sequencing following hybridization with probes derived from pLP32, which covered the slt-II coding region. The nucleotide sequence of approximately 1.5 kb of DNA spanning each of the toxin operons was determined for both strands, except that the nucleotide sequence of only one strand was determined for a small portion of the extreme 5' end of each A subunit gene. Because we had difficulty aligning the new toxin sequences with that of slt-II, the region of slt-II from pLP32 spanning positions 392 to 403 was resequenced. The plasmid pLP32 was derived from pNN76; the DNA sequence of the slt-IT operon was originally determined from pNN76 (10).
This region of slt-II was found to contain three additional nucleotide bases not present in the previously published sequence (10) . The revised sequence is presented here. These alterations result in the change of histidine (+45) to proline (+45) and the insertion of an additional proline (+46). 44, was a cytosine in slt-TI and an adenine in the toxin gene from pCKS111. Four base differences were found within the structural gene for the A subunit; none of these affected the amino acid sequence. However, 11 differences were found in the B subunit gene, which resulted in three amino acid substitutions (Fig. 3) slt-Ilc 
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DISCUSSION
In this study, 26% of the SLT-II-expressing enterohemorrhagic E. coli (EHEC) isolates examined contained two EcoRI chromosomal fragments that hybridized to slt-ITspecific DNA probes. Because none of the slt operons sequenced to date have contained an EcoRI site within or between the structural genes for the A and B polypeptides, we concluded that any EHEC strain with two slt-Il-hybridizing EcoRI fragments has two copies of slt-II-related genes. Whether each copy encodes a functional toxin was not determined, except for strain E32511. When the presence of two (or more) copies of related but distinct toxin genes in a designated -22 and -19, respectively, and the amino-terminal residues of the processed A and B subunits are designated +1. Restriction sites relevant to subcloning and slt-II-specific probe generation are as follows: Ha, HaeIII; Hc, HinclI; Ps, PstI; Sm, SmaI.
VOL. 59, 1991 clinical isolate goes unrecognized, any results obtained on the genetic and immunological characteristics of that strain may be erroneously interpreted. Furthermore, any toxin isolated to homogeneity from such a strain is potentially impure. Thus, the toxin prepared by Head et al. (6) from strain E32511 probably consists of the two comparable but not identical toxins, SLT-II and SLT-IIc. Similarly, the VT2 purified from EHEC B2F1 (30) is probably also impure because Ito et al. recently reported that this strain contains two closely related but distinct SLT-II-like toxins (9) . Furthermore, the VT2 isolated from EHEC strain J-2 (49) may also contain two populations of similar but not absolutely homologous toxins because our results suggest the possibility of two slt-II genes in that strain (Fig. 1) . Finally, VT2 has also been purified from strain E3657 (2), and it would be prudent to analyze this strain for additional copies of slt-II. The issue of two different types of SLTs in a preparation of purified toxin arose in this laboratory when we became aware through the finding of Scotland et al. (37a) that EHEC 933 expresses both SLT-I and SLT-II. The fact that the SLT-I we isolated from strain 933 was apparently pure (29a) was solely due to the facts that we used an antitoxin affinity column in our purification scheme and SLT-I and SLT-II are not immunologically cross-reactive (10) (Fig. 4) . However, the possibility of potentially contaminated toxin preparations prompted us to use toxin-converting phages (which to date have not been found to harbor two slt genes) or cloned toxin genes in E. coli K-12 strains for most purification purposes. Although E. coli strains that contain multiple copies of slt-I have not been identified (Table 3) , the finding of multiple slt-Il-related genes in EHEC strains argues strongly for the use of Southern analysis rather than colony hybridization to examine the distribution and types of toxins present in clinical isolates. Our detailed characterization of the two closely related toxin genes, slt-II and slt-IIc, from the E. coli 0157:Hstrain E32511 should clarify the literature concerning the nature of the toxin produced by E32511. The sequence homology between the two toxin operons in E32511 and slt-Il was the basis for naming each operon slt-1I, and the suffixes used to distinguish between genes for toxins that are very closely related but slightly different at the level of deduced amino acid sequence were consistent with Ito et al. (9) and Gannon et al. (4) .
It is likely that the toxin genes encoding slt-1I are present on a temperate bacteriophage. Willshaw et al. (48) reported the cloning of VT2 (E32511) from a 4.7-kb EcoRI fragment derived from bacteriophage XE32511. We found that the slt-II genes from E32511 were present on a 4.8-kb EcoRI fragment, whereas the slt-IIc genes were on a 5.5-kb EcoRI fragment. In addition, when we compared our restriction mapping data with those presented by Willshaw et al. (47) for 4E32511, a HincIl site was present in slt-II but absent from slt-IIc (Fig. 2, positions 1291 to 1296 ). The bacteriophages 4E32511 and +933W appear very similar morphologically, and both phages showed hybridization of slt-Il-specific sequences to a 5-kb EcoRI fragment (33) . It 49) . These differences in neutralization patterns could be due either to variations in the strains used to generate anti-SLT-II (or anti-VT2) or to differential expression of the toxin genes under various growth conditions. Yutsudo et al. (49) showed that the VT purified from strain J-2 was immunologically identical to both the cytotoxin produced by an E. coli B. 2El .s 6n- . Percent neutralization by several antibodies was determined by using bacterial lysates (see Materials and Methods for details). Antibodies used are as follows: SLT-II A subunit-specific antibodies llGlO (A) and 2E1 (B), SLT-II B subunit-specific antibody BC5 BB12 (C), and SLT-II-specific polyclonal rabbit antiserum AJ65 (D). Assays were done at least three times; data from a representative experiment are presented. The plasmids pCKS109 and pCKS111 express, respectively, SLT-II and SLT-IIc cloned from E32511; the plasmids pLP32 and pJES101 express, respectively, SLT-II and SLT-IIv (35) . All plasmids were maintained in nontoxinogenic E. coli DH5a. Symbols: O, E32511; *, pCKS109; 0, pCKS111; A, pLP32; 0, pJES101; A, Shiga toxin. K-12 strain lysogenized with (E32511 and SLT-II toxin, which supports our conclusion that the toxin genes present on 4E32511 are slt-II and not slt-Ilc.
Oku et al. (30) reported that purified toxin from B2F1 is 100-fold less cytotoxic for HeLa cells than for Vero cells. Although SLT-IIc is highly homologous to VT2vha of B2F1, we found that SLT-IIc was only slightly less cytotoxic for HeLa cells than for Vero cells. There are at least four possible explanations for this apparent discrepancy between our results and those of Oku et al. First, the toxin purified from B2F1 in 1989 (30) may have contained a mixture of VT2vha and VT2vhb, because at the time it was not recognized that B2F1 had two slightly different toxin operons. Second, the A subunit of SLT-IIc, which is very similar to but not identical to the A subunit of VT2vha, could be responsible for differences in relative toxicity of SLT-IIc and VT2vha for Vero and HeLa cells. Third, subtle changes between the conformations of VT2vha and SLT-IIc could alter the relative affinity or toxicity of the holotoxins for Vero and/or HeLa cells. Indeed, we found that monoclonal antibodies to either the A or B subunit of SLT-II could distinguish between SLT-II and SLT-IIc. Since the A subunits of SLT-IIc and SLT-II are identical but the B subunits vary, the B subunit amino acid differences between SLT-IIc and SLT-II must have altered the conformation of SLT-IIc sufficiently to affect reactivity with A subunit-specific monoclonal antibodies. A fourth explanation is that variations in the sensitivities of different HeLa cell lines to toxins may account for differences seen in relative cytotoxicities among laboratories.
Neutralization assays showed that the cytotoxic activity in sonically disrupted preparations of E32511 was phenotypically more like SLT-II than SLT-IIc. It is possible that slt-II could be expressed better than slt-IIc by E32511, although the only apparent difference in the regulatory regions of slt-IT and slt-Ilc was the first nucleotide of the -35 region. SLT-II could also be intrinsically more stable or have a higher specific activity than SLT-IIc. Alternatively, a pool of both types of B subunits, which is presumably present in E32511, may form heterologous pentameric B subunits that can be neutralized efficiently by antibodies directed against SLT-II.
The importance of multiple copies of slt-II in strains of E. coli associated with disease remains to be determined. However, it should be noted that Ostroff et al. (31) and Tarr et al. (43) found that E. coli 0157:H7 strains that contained only slt-II genes were more frequently associated with HUS and thrombocytopenic purpura than strains containing slt-I or both slt-I and slt-II. In a study of E. coli 0157 strains isolated in Great Britain, Scotland et al. (38) also noted that strains producing SLT-II alone were most frequently associated with HUS. A 3-year detailed study of HUS in children in the British Isles also showed a strong correlation between SLT-II-producing strains and HUS (13, 23) . Wadolkowski et al. found that SLT-II-but not SLT-I-producing E. coli strains were able to kill mice in the murine model system (45, 45a) . Thus, a link has been established between the presence of slt-IT genes and disease-causing E. coli 0157 strains. Whether multiple copies of slt-TI operons are responsible for enhanced virulence of an EHEC strain remains to be determined.
